MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies

Clinical Use

Use

This test is designed for evaluating multiple myeloma at the time of diagnosis and at disease relapse. It provides prognostic information and determines potential therapeutic implications. Next-generation sequencing (NGS) technology enables detailed evaluation of multiple myeloma genetics, allowing for further risk categorization through the identification of genetic abnormalities that have prognostic and potential therapeutic value. This test includes next-generation sequencing of 26 genes: BIRC3, BRAF, CCND1, CDKN2A, CRBN, CUL4A, CUL4B, CXCR4, DIS3, EGFR, IDH1, IDH2, IKZF1, IKZF3, KRAS, MYC, MYD88, NRAS, NSD2, PIK3CA, PIM1, STAT3, TENT5C, TP53, TRAF3, and XBP1.

Special Instructions

Not provided.

Limitations

This NGS panel is targeted and will not detect genetic abnormalities outside the specified 26 genes. It detects single base substitutions and small insertion/deletion type events but is not configured to detect gene fusions, large-scale deletions, or structural genomic rearrangements. The test does not differentiate between somatic and germline alterations. Inadequate samples or prior treatment effects may impact results. NGS should not be pursued if the initial plasma cell percentage is below 5%.

Test Details

New York Approved